News Obesity biotech Kalohexis files confidential IPO Just weeks after forming as a spinout from Endevica Bio, obesity drug developer Kalohexis has filed for an IPO.
News Scribe Therapeutics joins the IPO queue Scribe Therapeutics has become the latest biotech to announce plans to list on the Nasdaq as it advances its spin on CRISPR-based therapeutics.
News Respiratory biotech Celea raises $180m, and other financings This week's collection of venture capital financings in the biotech arena includes rounds for Celea, Beeline, Flare, Lycia, and Telum.
News Hub-and-spoke firm Osanni raises $190m, and other financings Our latest roundup of venture capital financings in the biotech sector includes rounds for Osanni Bio, Bionyra, Serapha, Nura Bio, and Oblenio.
News Bispecific antibody firm Ollin raises $330m in bumper round Ollin has followed its $100m Series A last year with a massive $330m second round that will fund phase 3 trials of its challenger to Roche's Vabysmo.
News UK's RQ Bio raises $115m for flu prevention drug RQ Bio has raised $115m for clinical trials of RQB01, a one-shot antibody designed for strain-agnostic protection against seasonal influenza viruses.
News Lundbeck preps for key bexicaserin data around year-end Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
